143 related articles for article (PubMed ID: 37721661)
1. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma.
Yamaoka K; Irie K; Hiramoto N; Hirabatake M; Ikesue H; Hashida T; Shimizu T; Ishikawa T; Muroi N
Invest New Drugs; 2023 Oct; 41(5):761-767. PubMed ID: 37721661
[TBL] [Abstract][Full Text] [Related]
2. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Mateos MV; Rigaudeau S; Basu S; Spicka I; Schots R; Wrobel T; Cook G; Beksac M; Gries KS; Kudva A; Tromp B; Van Rampelbergh R; Pei H; Wroblewski S; Carson R; Delioukina M; White D
J Oncol Pharm Pract; 2023 Jul; 29(5):1172-1177. PubMed ID: 36067063
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
[TBL] [Abstract][Full Text] [Related]
5. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
[TBL] [Abstract][Full Text] [Related]
7. Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro-costing analysis in three Italian hematology centers.
Pradelli L; Massaia M; Todisco E; Gherlinzoni F; Furlan A; La Targia M; Grande E; Tripoli IE; Occhipinti F; Comello F; Iannello F; Bellucci S
Cancer Med; 2023 Dec; 12(23):21480-21489. PubMed ID: 37942566
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Shibayama H; Matsumoto M; Kosugi H; Shibayama K; Yamazaki H; Iida S
Int J Hematol; 2021 Jan; 113(1):112-121. PubMed ID: 32915384
[TBL] [Abstract][Full Text] [Related]
9. Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers.
Cook G; Ashcroft J; Fernandez M; Henshaw S; Khalaf Z; Pratt G; Tailor A; Rabin N
Front Oncol; 2023; 13():1063144. PubMed ID: 36910662
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
[TBL] [Abstract][Full Text] [Related]
11. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.
Soefje SA; Carpenter C; Carlson K; Awasthi S; Lin TS; Kaila S; Tarjan D; Kayal N; Kirkup C; Wagner TE; Gray KS; Kumar S
JCO Oncol Pract; 2023 Apr; 19(4):e542-e549. PubMed ID: 36758192
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010).
An G; Ge Z; Jing H; Liu J; Yang G; Feng R; Xu Z; Qi M; Wang J; Song J; Zhou W; Sun B; Zhu D; Chen X; Cui C; Qiu L
Blood Sci; 2024 Jul; 6(3):e00193. PubMed ID: 38832105
[TBL] [Abstract][Full Text] [Related]
13. Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab.
Vazirnia D; Del Rio Verduzco A; Soefje SA; Sanders KA; Sandahl TB
JCO Oncol Pract; 2024 Feb; ():OP2300470. PubMed ID: 38408288
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
Paul B; Hamadeh I; Atrash S; Bhutani M; Voorhees P; Usmani SZ
Expert Opin Biol Ther; 2020 Nov; 20(11):1253-1259. PubMed ID: 32750265
[TBL] [Abstract][Full Text] [Related]
15. Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R
Front Oncol; 2022; 12():851864. PubMed ID: 35359355
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
[TBL] [Abstract][Full Text] [Related]
17. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS; Moore DC; Martin A; Karabinos A; Hill H; Ndiaye A; Robinson JD; Paul BA; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):470-475. PubMed ID: 33785299
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting.
Tam AH; Jung Y; Young R; Huang CY; Wolf J; Shah N; Wong SW; Martin TG; Lo M
J Oncol Pharm Pract; 2022 Dec; 28(8):1819-1825. PubMed ID: 34647506
[TBL] [Abstract][Full Text] [Related]
20. Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.
Xu Y; Deng S; Mao X; An G; Li Z; Wang Y; Fulciniti M; Ho M; Lin J; Sui W; Liu W; Zou D; Yi S; Huang W; Liu H; Lv R; Li J; Wang T; Du C; Munshi NC; Qiu L
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):422-430. PubMed ID: 29625927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]